B-type natriuretic peptide as a predictor of ischemia/reperfusion injury immediately after myocardial reperfusion in patients with ST-segment elevation acute myocardial infarction
Restricted accessResearch articleFirst published online February, 2016
B-type natriuretic peptide as a predictor of ischemia/reperfusion injury immediately after myocardial reperfusion in patients with ST-segment elevation acute myocardial infarction
In animal models of acute myocardial infarction (AMI), B-type natriuretic peptide (BNP) administered before and during coronary occlusion limits infarct size. However, the relation between plasma BNP levels and ischemia/reperfusion injury remains unclear.
Methods:
302 patients with ST-segment elevation AMI (STEMI) received emergency percutaneous coronary intervention within six hours from the onset. The patients were divided into two groups according to the plasma BNP level before angiography: group L (n=151), BNP ≤32.2 pg/ml; group H (n=151), BNP >32.2 pg/ml. The Selvester QRS-scoring system was used to estimate infarct size.
Results:
The rate of ischemia/reperfusion injury immediately after reperfusion, defined as reperfusion ventricular arrhythmias (26% vs. 11%, p=0.001) and ST-segment re-elevation (44% vs. 22%, p=0.008), was higher in group L than in group H. Group L had a greater increase in the QRS score during percutaneous coronary intervention (3.55±0.17 vs. 2.09±0.17, p<0.001) and a higher QRS score 1 h after percutaneous coronary intervention (5.77±0.28 vs. 4.51±0.28, p=0.002). On multivariate analysis, plasma BNP levels in the lower 50th percentile were an independent predictor of reperfusion injury (odds ratio, 2.620; p<0.001). The odds ratios of reperfusion injury according to decreasing quartiles of BNP level, as compared with the highest quartile, were 1.536, 3.692 and 4.964, respectively (p trend=0.002).
Conclusions:
Plasma BNP level before percutaneous coronary intervention may be a predictor of ischemia/reperfusion injury and the resultant extent of myocardial damage. Our findings suggest that high plasma BNP levels might have a clinically important protective effect on ischemic myocardium in patients with STEMI who receive percutaneous coronary intervention.
HausenloyDJDuchenMRYellonDM. Inhibiting mitochondrial permeability transition pore opening at reperfusion protects against ischemia-reperfusion injury. Cardiovasc Res2003; 60: 617–625.
2.
TerkelsenCJKaltoftAKNørgaardBL. ST changes before and during primary coronary intervention predict final infarct size in patients with ST elevation myocardial infarction. J Electrocardiol2009; 42: 64–72.
3.
TerkelsenCJNørgaardBLLassenJF. Potential significance of spontaneous and interventional ST-changes in patients transferred for primary percutaneous coronary intervention: Observations from the ST-MONitoring in Acute Myocardial Infarction study (The MONAMI study). i 2006; 27: 267–275.
4.
TerkelsenCJSørensenJTKaltoftAK. Prevalence and significance of accelerated idioventricular rhythm in patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention. Am J Cardiol2009; 104: 1641–1646.
5.
EngelenDJGressinVKrucoffMW. Usefulness of frequent arrhythmias after epicardial recanalization in anterior wall acute myocardial infarction as a marker of cellular injury leading to poor recovery of left ventricular function. Am J Cardiol2003; 92: 1143–1149.
MajidiMKosinskiASAl-KhatibSM. Reperfusion ventricular arrhythmia ‘bursts’ in TIMI 3 flow restoration with primary angioplasty for anterior ST-elevation myocardial infarction: A more precise definition of reperfusion arrhythmias. Europace2008; 10: 988–997.
8.
PiotCCroisillePStaatP. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med2008; 359: 473–481.
9.
KitakazeMAsakuraMKimJ.; J-WIND investigators. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): Two randomised trials. Lancet2007; 370: 1483–1493.
10.
D’SouzaSPDavisMBaxterGF. Autocrine and paracrine actions of natriuretic peptides in the heart. Pharmacol Ther2004; 101: 113–129.
11.
D’SouzaSPYellonDMMartinC. B-type natriuretic peptide limits infarct size in rat isolated hearts via KATP channel opening. Am J Physiol Heart Circ Physiol2003; 284: 1592–1600.
12.
BurleyDSBaxterGF. B-type natriuretic peptide at early reperfusion limits infarct size in the rat isolated heart. Basic Res Cardiol2007; 102: 529–541.
13.
FeldmanLJHimbertDJuliardJM. Reperfusion syndrome: Relationship of coronary blood flow reserve to left ventricular function and infarct size. J Am Coll Cardiol2000; 35: 1162–1169.
14.
YellonDMHausenloyDJ. Myocardial reperfusion injury. N Engl J Med200713; 357: 1121–1135.
15.
MatetzkySNovikovMGrubergL. The significance of persistent ST elevation versus early resolution of ST segment elevation after primary PTCA. J Am Coll Cardiol1999; 34: 1932–1938.
16.
Van’t HofAWJLiemASuryapranataH. Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction. Circulation1998; 97: 2302–2306.
17.
SelvesterRHWagnerGSHindmanNB. The Selvester QRS scoring system for estimating myocardial infarct size. The development and application of the system. Arch Intern Med1985; 145: 1877–1881.
18.
ClaeysMJBosmansJVeenstraL. Determinants and prognostic implications of persistent ST-segment elevation after primary angioplasty for acute myocardial infarction: Importance of microvascular reperfusion injury on clinical outcome. Circulation1999; 99: 1972–1977.
19.
IliaRAmitGCafriC. Reperfusion arrhythmias during coronary angioplasty for acute myocardial infarction predict ST-segment resolution. Coron Artery Dis2003;14: 439–441.
20.
ChiladakisJAPashalisAPatsourasN. Autonomic patterns preceding and following accelerated idioventricular rhythm in acute myocardial infarction. Cardiology2001; 96: 24–31.
21.
HohnloserSHZabelMKasperW. Assessment of coronary artery patency after thrombolytic therapy: Accurate prediction utilizing the combined analysis of three noninvasive markers. J Am Coll Cardiol1991; 18: 44–49.
22.
MonassierJP. Reperfusion injury in acute myocardial infarction. From bench to cath lab. Part I: Basic considerations. Arch Cardiovasc Dis2008; 101: 491–500.
23.
HasegawaKFujiwaraHItohH. Light and electron microscopic localization of brain natriuretic peptide in relation to atrial natriuretic peptide in portine atrium. Immunohistocytochemical study using specific monoclonal antibodies. Circulation1991; 84: 1203–1209.
HinoJTateyamaHMinaminoN. Isolation and identification of human brain natriuretic peptides in cardiac atrium. Biochem Biophys Res Commun1990; 167: 693–700.
26.
SabatineMSMorrowDAde LemosJA. Acute changes in circulating natriuretic peptide levels in relation to myocardial ischemia. J Am Coll Cardiol2004; 44: 1988–1995.
27.
TateishiJMasutaniMOhyanagiM. Transient increase in plasma brain (B-type) natriuretic peptide after percutaneous transluminal coronary angioplasty. Clin Cardiol2000; 23: 776–780.
28.
HamaNItohHShirakamiG. Rapid ventricular induction of brain natriuretic peptide gene expression in experimental acute myocardial infarction. Circulation1995; 92: 1558–1564.
29.
OgawaASeinoYYamashitaT. Difference in elevation of N-terminal pro-BNP and conventional cardiac markers between patients with ST elevation vs. non-ST elevation acute coronary syndrome. Circ J2006; 70: 1372–1378.
30.
MoritaEYasueHYoshimuraM. Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction. Circulation1993; 88: 82–91.
31.
de LemosJAMorrowDABentleyJH. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med2001; 345: 1014–1021.
32.
MegaJLMorrowDAde LemosJA. B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction: An ENTIRE-TIMI-23 substudy. J Am Coll Cardiol2004; 44: 335–339.
33.
PalazzuoliAGennariLCalabriaP. Relation of plasma brain natriuretic peptide levels in non-ST-elevation coronary disease and preserved systolic function to number of narrowed coronary arteries. Am J Cardiol200515; 96: 1705–1710.
34.
FlahertyJTPittBGruberJW. Recombinant human superoxide dismutase (h-SOD) fails to improve recovery of ventricular function in patients undergoing coronary angioplasty for acute myocardial infarction. Circulation1994; 89: 1982–1991.
35.
ThérouxPChaitmanBRDanchinN. Inhibition of the sodium-hydrogen exchanger with cariporide to prevent myocardial infarction in high-risk ischemic situations. Main results of the GUARDIAN trial. Guard during ischemia against necrosis (GUARDIAN) Investigators. Circulation2000; 102: 3032–3038.
36.
BaranKWNguyenMMcKendallGR.; Limitation of Myocardial Infarction Following Thrombolysis in Acute Myocardial Infarction (LIMIT AMI) Study Group. Double-blind, randomized trial of an anti-CD18 antibody in conjunction with recombinant tissue plasminogen activator for acute myocardial infarction: Limitation of myocardial infarction following thrombolysis in acute myocardial infarction (LIMIT AMI) study. Circulation2001;104: 2778–2783.
